These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB; Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486 [TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study. Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y Am J Hematol; 2024 Feb; 99(2):E55-E59. PubMed ID: 38165064 [No Abstract] [Full Text] [Related]
7. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study. Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME; Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598 [TBL] [Abstract][Full Text] [Related]
8. Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience. Moore DC; Elmes JB; Arnall JR; Pineda-Roman M Blood Coagul Fibrinolysis; 2024 Sep; 35(6):316-320. PubMed ID: 39012641 [TBL] [Abstract][Full Text] [Related]
10. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study. Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y; Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677 [TBL] [Abstract][Full Text] [Related]
11. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk. Mehta AR; Kefela A; Toste C; Sweet D Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873 [TBL] [Abstract][Full Text] [Related]
12. Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia. Mingot-Castellano ME; Bastida JM; Ghanima W; Ruiz Sainz E; Nuñez Vazquez R; Pedrote Amador B; Abdel-Kader Martín L; Piquer-Monsonis D; Canaro M Br J Haematol; 2024 Oct; 205(4):1551-1555. PubMed ID: 38895923 [TBL] [Abstract][Full Text] [Related]
13. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. Kuter DJ; Rogers KA; Boxer MA; Choi M; Agajanian R; Arnold DM; Broome CM; Field JJ; Murakhovskaya I; Numerof R; Tong S Am J Hematol; 2022 Jun; 97(6):691-699. PubMed ID: 35179251 [TBL] [Abstract][Full Text] [Related]
14. Fostamatinib for the treatment of immune thrombocytopenia in adults. Moore DC; Gebru T; Muslimani A Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590 [TBL] [Abstract][Full Text] [Related]
15. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients. Dierickx D; Neefs J Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338 [TBL] [Abstract][Full Text] [Related]
16. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632 [TBL] [Abstract][Full Text] [Related]
17. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist. Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285 [TBL] [Abstract][Full Text] [Related]
18. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Ghanima W; Gernsheimer T; Kuter DJ Blood; 2021 May; 137(20):2736-2744. PubMed ID: 33827138 [TBL] [Abstract][Full Text] [Related]
19. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874 [TBL] [Abstract][Full Text] [Related]